barefootrunner, I just reread MattoRuu message from earlier.
In reading it and looking more at what is said on each level, it appears that moderate and highly emetogenic chemotherapy are better than Aloxi based on the numbers I am seeing from the research in that message posting. Albeit maybe not showing "superiority" over Aloxi in highly emetogenic chemotherapy percentage, I will take the smaller higher percentage results as it is. That plus this new drug can be, but is not required to be, used through an IV. Where Aloxi can ONLY be used through an IV.
Unless I am not understanding what I am reading, I guess as I see it, in my opinion, this product is better than Aloxi as it can be administered to a patient in many different ways, is at least even if not better than Aloxi (though maybe not superior in their definition) in the numbers I have seen that are shown below in the prior posting from MattoRuu.
Now if people are selling this stock due to it not be "statistically superior" to Aloxi, yet this new drug is better (in my mind) then let them sell their shares off as I will take up more myself. I can not image the the FDA would not approve this drug based on these findings of being equal or better in aspects to Aloxi, and that it has a much better way to administer their drug to the patient.
APF530's Complete Response percentage has been shown to be better than Aloxi Complete Response percentage, indicating that it is more effective than Aloxi in the areas of acute and delayed CINV for both moderate emetogenic chemotherapy treatment and highly emetogenic chemotherapy treatment.
APF530's CR percentage for acute onset CINV following moderate emetogenic chemotherapy is better than Aloxi's CR percentage (77.9% for APF530 vs. 75% for Aloxi).
APF530's CR percentage for delayed onset CINV following moderate emetogenic chemotherapy is better than Aloxi's CR percentage (81.3% for APF530 vs. 80.7% for Aloxi).
APF530's CR percentage for acute onset CINV following highly emetogenic chemotherapy is better than Aloxi's CR percentage (59% for APF530 vs. 57.7% for Aloxi).
APF530's CR percentage for delayed onset CINV following highly emetogenic chemotherapy is better than Aloxi's CR percentage (68.3% for APF530 vs. 66.4% for Aloxi).
AI
